The trial is taking place at:

ONCOVIDA | Santiago, Chile

Veeva-enabled site

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Phase 2


Carcinoma, Hepatocellular
Biliary Tract Neoplasms
Pancreatic Ductal Adenocarcinoma
Colorectal Neoplasms
Esophageal Neoplasms
Endometrial Neoplasms


Drug: Pembrolizumab
Drug: Lenvatinib
Drug: Belzutifan

Study type


Funder types



MK-6482-016 (Other Identifier)
2020-005007-40 (EudraCT Number)

Details and patient eligibility


The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.


730 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Diagnosis of one of the following advanced (unresectable and/or metastatic) solid tumors, documented by histopathology or cytopathology:

    • Hepatocellular carcinoma (HCC)
    • Colorectal cancer (CRC) (non-microsatellite instability-high [non-MSI-H]/deficient mismatch repair [dMMR])
    • Pancreatic ductal adenocarcinoma (PDAC).
    • Biliary tract cancer (BTC) (includes intrahepatic, extrahepatic cholangiocarcinoma [CCA] and gall bladder cancer)
    • Endometrial cancer (EC)
    • Esophageal squamous cell carcinoma (ESCC)
  • Disease progression on or since the most recent treatment (does not apply to newly diagnosed unresectable or metastatic HCC or EC).

  • Measurable disease per RECIST v1.1 as assessed locally (by investigator) and verified by BICR

  • Submission of an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated

  • Male participants are abstinent from heterosexual intercourse or agree to follow contraceptive guidance during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib

  • Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP), or is a WOCBP and agrees to follow contraceptive guidance during the intervention period and and for at least 120 days after the last dose of pembrolizumab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last

  • Adequate organ function

  • Adequately controlled blood pressure with or without antihypertensive medications

  • HCC Specific Inclusion Criteria: No prior systemic chemotherapy, including anti-VEGF therapy, anti-programmed cell-death (PD-1)/PD-L1 or any systemic investigational anticancer agents for advanced/unresectable HCC (1L)

  • CRC ([non-MSI-H/dMMR) Specific Inclusion Criteria: Received at least 2 prior lines of systemic therapy for unresectable or metastatic disease which includes fluoropyrimidine, irinotecan and oxaliplatin

  • PDAC Specific Inclusion Criteria: Prior therapy with at least 1 (platinum or gemcitabine containing regimen) but no more than 2 prior systemic therapies for unresectable or metastatic pancreatic cancer

  • BTC Specific Inclusion Criteria: Received at least 1 prior line of systemic therapy (containing gemcitabine or fluoropyrimidine) for unresectable or metastatic disease

  • EC Specific Inclusion Criteria: Study treatment is for 1L therapy of EC and participants should not have received prior systemic chemotherapy. Exception: May have received 1 prior line of line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of a curative-intent resection, if the recurrence occurred ≥6 months after the last dose of chemotherapy or may have received prior radiation with or without chemotherapy

  • ESCC Specific Inclusion Criteria: Have experienced radiographic or clinical progression on one prior line of standard systemic therapy (immune oncology (IO) naïve participants) or an anti-PD-1/PD-L1 (IO resistant participants)

Exclusion criteria

  • Unable to swallow orally administered medication or presence of a gastrointestinal (GI) disorder that may affect study intervention absorption
  • History of a second malignancy that is progressing or has required active treatment within 3 years
  • A pulse oximeter reading <92% at rest, or requirement of intermittent supplemental oxygen/ chronic supplemental oxygen
  • Presence of central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Clinically significant cardiovascular disease within 6 months of first dose of study intervention
  • Symptomatic pleural effusion, unless clinically stable after treatment
  • Preexisting ≥ Grade 3 gastrointestinal (GI) or non-GI fistula
  • Moderate to severe hepatic impairment
  • Clinically significant history of bleeding within 3 months before screening
  • Presence of serious active nonhealing wound/ulcer/bone fracture
  • Requirement for hemodialysis or peritoneal dialysis
  • History of human immunodeficiency virus (HIV) infection
  • History of Hepatitis B or active Hepatis C virus infections. with exceptions for HCC and BTC
  • Prior therapy with a PD-1, anti-PD-L1, anti-PD-L2 agent, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) or hypoxia-inducible factor 2α (HIF-2α)
  • Radiographic evidence of intratumoral cavitation, or invasion/infiltration of a major blood vessel
  • EC specific exclusion criteria: History of carcinosarcoma, endometrial leiomyosarcoma or other high-grade sarcomas, or endometrial stromal sarcomas
  • ESCC specific exclusion criteria: Has clinically apparent ascites or pleural effusion or experienced weight loss >20% over approximately 3 months before first dose of study therapy

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

730 participants in 2 patient groups

Arm 1: Pembrolizumab + Belzutifan + Lenvatinib
Experimental group
Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg (For HCC: 8 mg \[body weight \<60kg\] or 12 mg \[body weight ≥ 60 kg\]). Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
Drug: Belzutifan
Drug: Lenvatinib
Drug: Pembrolizumab
Arm 2: Pembrolizumab + Lenvatinib
Experimental group
Participants with IO resistant ESCC will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
Drug: Lenvatinib
Drug: Pembrolizumab

Trial contacts and locations



Central trial contact

Toll Free Number

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems